Visualizing the landscape of selection biomarkers in current phase III oncology clinical trials.
Selection biomarkers are disease-associated analytes whose measurement is either an essential step in patient screening or the primary objective of a clinical trial. The public database ClinicalTrials.gov contains information on most active phase III oncology clinical trials that can be examined for trends in the development of cancer therapies. But for selection biomarkers, such information is not easily accessible and so has not been examined in a comprehensive way. Here we provide a global analysis of selection biomarkers currently in use in the oncology phase III trial arena.
Amgen, Thousand Oaks, CA 91320, USA. public@robertsikorski.com
Robert
R
Sikorski
Bin
B
Yao
D014408:Biomarkers, Tumor / Q000378:metabolism*; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D018579:Patient Selection
D014408:Biomarkers, Tumor